{"nctId":"NCT03125395","briefTitle":"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","startDateStruct":{"date":"2017-05-12","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":57,"armGroups":[{"label":"LUM/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: LUM/IVA"]}],"interventions":[{"name":"LUM/IVA","otherNames":["VX-809/VX-770","lumacaftor/ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects entering the Treatment Cohort must meet the following criteria:\n\n* Completed 24 weeks of LUM/IVA treatment and the Safety Follow-up Visit in Study VX15-809-115 Part B (Study 115B, NCT02797132)\n* Willing to remain on a stable CF medication regimen through the Safety Follow-up Visit\n\nSubjects entering the Observational Cohort must meet 1 of the following criteria:\n\n* Completed 24 weeks of LUM/IVA treatment and the Safety Follow-up Visit in Study 115B, but do not want to enroll in the Treatment Cohort.\n* Received at least 4 weeks of LUM/IVA treatment and completed visits up to Week 24 and the Safety Follow-up Visit, if required, of Study 115B but are not taking LUM/IVA at the end of the Study 115B Treatment Period (i.e., Week 24) because of a drug interruption and either did not receive Vertex approval to enroll in the Treatment Cohort or do not want to enroll in the Treatment Cohort.\n* Permanently discontinued LUM/IVA in Study 115B after receiving at least 4 weeks of treatment and remained in the study from the time of treatment discontinuation through the Week 24 Visit and Safety Follow-up Visit, if required.\n\nExclusion Criteria (Treatment Cohort Only):\n\n* Prematurely discontinued LUM/IVA treatment in Study 115B.\n* History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering LUM/IVA to the subject\n* History of drug intolerance or other serious reactions to LUM/IVA in Study 115B that would pose an additional risk to the subject in the opinion of investigator, and which should be discussed with the Vertex medical monitor.\n* Subjects with a history of allergy or hypersensitivity to LUM/IVA.\n* Liver function test (LFT) abnormality meeting criteria for LUM/IVA treatment interruption at the completion of Study 115B, for which no convincing alternative etiology is identified.\n* QTc value at the completion of Study 115B that would pose an additional risk to the subject in the opinion of investigator, and which should be discussed with the Vertex medical monitor\n* History of poor compliance with LUM/IVA and/or procedures in Study 115B as deemed by the investigator.\n* Participation in an investigational drug trial (including studies investigating LUM and/or IVA) other than Study 115B.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride","description":"Sweat samples were collected using an approved collection device.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.6","spread":"12.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in BMI-for-age Z-score","description":"BMI was defined as weight in kilograms divided by height in m\\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Weight-for-age Z-score","description":"Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Stature (Height)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Stature-for-age Z-score","description":"Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Time-to-first Pulmonary Exacerbation","description":"Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"600.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations (PEx)","description":"Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Cystic Fibrosis (CF) Related Hospitalizations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Fecal Elastase-1 (FE-1) Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.6","spread":"174.2"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-108.5","spread":"306.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Microbiology Culture Status (Positive or Negative)","description":"Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Lung Clearance Index (LCI) 2.5","description":"LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Lung Clearance Index (LCI) 5.0","description":"LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.65"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":57},"commonTop":["Cough","Nasal congestion","Pyrexia","Rhinorrhoea","Vomiting"]}}}